RESUMEN
We studied N-myc oncogene expression in 13 human neuroectodermal tumors and one teratoma by in situ hybridization. In four of six neuroblastomas, there was increased N-myc expression (15 to 49% of the cells). Many of the primitive neuroblastic cells had an increase of N-myc RNA not observed in the larger, more differentiated cells. Two neuroblastomas matured to ganglioneuromas; no biopsies performed during this progression expressed increased N-myc RNA. Three ganglioneuroblastomas, two tumors presenting as ganglioneuromas, a cerebral neuroectodermal tumor, a neurofibrosarcoma, and the teratoma did not have increased N-myc expression. The data obtained by in situ hybridization correlated well with data obtained by blot analysis. Neuroblastomas/ganglioneuroblastomas with a favorable course did not have appreciable elevation of N-myc expression over 10 to 77 mo of follow-up; thus N-myc may not be involved in the maintenance of the neoplastic state. However, such tumors with a fatal outcome 2 to 14 mo after diagnosis usually had elevated N-myc expression. These findings suggest a relationship between elevated levels of N-myc RNA and poor prognosis.
Asunto(s)
Neuroblastoma/genética , Hibridación de Ácido Nucleico , Oncogenes , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Diferenciación Celular , Transformación Celular Neoplásica , Preescolar , Ganglioneuroma/genética , Ganglioneuroma/patología , Amplificación de Genes , Humanos , Lactante , Neuroblastoma/patología , ARN/análisisRESUMEN
We report treatment results in 93 children entered on study from 1978 to 1984 with malignant germ cell tumors (MGCTs), excluding dysgerminoma and tumors of the testis or brain. The estimated 4-year survival and event-free survival (EFS) for all 93 patients were 54% and 49%, respectively. For 30 children with ovarian tumors, the estimated 4-year survival was 67% and EFS was 63%. For 63 children with nongonadal tumors, survival and EFS were 48% and 42%, respectively. The comparison of EFS between ovarian and nongonadal tumors was significant at P = .03. The treatment plan included a second-look surgical procedure after 18 weeks of chemotherapy. Over half of 36 patients evaluated as having a residual mass present immediately before second-look surgery had no malignant tumor after review of surgical specimens. Age greater than 11 years at diagnosis, incomplete removal of tumor at first surgery, and more than one structure or organ involved at diagnosis increased the risk for adverse event. The histologic subtype of the primary tumor was not related to outcome. Diagnosis was verified by independent pathologic review, and treatment was uniform. Seventeen percent of all registered patients (21 of 127) were excluded because of ineligible pathologic diagnoses; sixty percent (13 of 21) were immature teratomas.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de Células Germinales y Embrionarias/terapia , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Bleomicina/administración & dosificación , Niño , Preescolar , Cisplatino/administración & dosificación , Terapia Combinada , Ciclofosfamida/administración & dosificación , Dactinomicina/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Humanos , Lactante , Masculino , Pronóstico , Reoperación , Análisis de Supervivencia , Vinblastina/administración & dosificaciónRESUMEN
PURPOSE: On past Childrens Cancer Group (CCG) trials, children with acute lymphoblastic leukemia and unfavorable presenting features had obtained an event-free survival (EFS) rate of no better than 50%. Following promising pilot experience, this study was conducted to determine the benefit and morbidity of two intensive experimental regimens, Reg A, based on the Berlin-Frankfurt-Münster (BFM) 1976 regimen, and Reg B, the New York regimen. PATIENTS AND METHODS: Between February 1983 and November 1984, 217 eligible children with acute lymphoblastic leukemia and unfavorable presenting features were entered and randomly assigned to receive Reg A, Reg B, or Reg C, the control regimen. Assignment to Reg C was halted in November 1984 after interim analyses showed an inferior outcome. Subsequently, between November 1984 and March 1987, an additional 328 patients were randomly allocated to receive Reg A or Reg B. RESULTS: The 7-year EFS rate was 63% (+/- 6%, 1 SD) for Reg A, 61% (+/- 6%) for Reg B, and 40% (+/- 6%) for Reg C (P < .006). The difference between Reg A or Reg B and Reg C remained greater than 20 percentage points for EFS at 7 years and 15 percentage points for survival. Relative to Reg C, patients on Reg A accrued 16.3 additional days of hospitalization on average and, on Reg B, 20.2 days. EFS and survival were similar on Reg A and Reg B, but Reg B required more days of parenteral therapy and greater exposure to anthracyclines and alkylating agents. CONCLUSION: Both Reg A and Reg B provided a better outcome than Reg C for children with acute lymphoblastic leukemia and unfavorable presenting features. Outcomes on Reg A and Reg B were similar. Use of the more effective but more toxic regimens resulted in 78 additional hospital days per relapse prevented on Reg A and 101 days on Reg B. The current CCG trial for this population builds on Reg A.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Adolescente , Adulto , Niño , Preescolar , Terapia Combinada , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Lactante , Tiempo de Internación , Tablas de Vida , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/radioterapia , Modelos de Riesgos Proporcionales , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
The Childrens Cancer Study Group (CCSG) undertook a study (CCG-823F) to test the feasibility of administering continuous infusion doxorubicin (CI DOX) and cisplatin (CDDP) in patients with unresectable or incompletely resected hepatoblastoma (HB) or hepatocellular carcinoma (HCC). Chemotherapy consisted of CI DOX 20 mg/m2/d for days 1 to 4 and CDDP 100 mg/m2 on day 1 followed by a 21-day rest period. Second-look surgery was performed after the administration of four chemotherapy courses. Forty-seven (47) assessable patients were entered on study, 33 with HB and 14 with HCC; of these, 34 (26 HB and eight HCC) completed the initial four courses of chemotherapy. Of the 26 HB patients, 25 were evaluated as responding to chemotherapy before the scheduled second-look procedure and were considered surgically resectable at that time. Surgery was performed on 22 patients; three patients refused the second-look surgery. Nine patients had no evidence of residual malignant disease, seven underwent surgical resection of remaining tumor, four were left with microscopic residual disease, one had a partial resection with gross tumor left behind, and one remained unresectable. Nine HCC patients completed four chemotherapy courses. Eight patients achieved a partial remission and second-look surgery was attempted on seven. Only two had all malignant disease removed at the second procedure. Data from 225 courses of chemotherapy were evaluated for toxicity. Neutropenia (absolute granulocyte count less than 500/mL) was observed in 68 courses, and five of these episodes were associated with sepsis. Severe mucositis was documented in 21 courses, and hypomagnesemia (magnesium less than 1.2 mg) was noted in 30 patients. Two patients developed decreased left ventricular shortening fraction, which resolved when chemotherapy was discontinued. In summary, CI DOX plus CDDP is a well-tolerated and effective regimen in inducing surgical resectability in HB patients who are unresectable at diagnosis and significantly improves survival for this group of patients to 66.6%.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma Hepatocelular/patología , Carcinoma Hepatocelular/secundario , Niño , Preescolar , Cisplatino/administración & dosificación , Terapia Combinada , Doxorrubicina/administración & dosificación , Estudios de Factibilidad , Femenino , Ferritinas/sangre , Humanos , Lactante , Infusiones Intravenosas , Neoplasias Hepáticas/patología , Masculino , Reoperación , Análisis de Supervivencia , alfa-Fetoproteínas/análisisRESUMEN
Prophylactic central nervous system treatment has dramatically improved the disease-free survival of children with acute lymphoblastic leukemia (ALL). Long-term neuropsychological sequelae are documented in children who received 2400 cGy prophylactic cranial irradiation. The dose was reduced to 1800 cGy. Available reports on developmental consequences, with short follow-up, have yielded inconsistent results. This study assesses radiation dose effects on cognitive function in children with leukemia who received central nervous system prophylaxis with 2400 cGy versus 1800 cGy whole brain radiotherapy. All leukemic children also received intrathecal methotrexate. A control group of children (treated for Wilms' tumor) received no central nervous system therapy. Nineteen children were treated with 2400 cGy, 16 children with 1800 cGy. The 12 control children received no irradiation. All patients were off therapy for at least 70 months. The 1800 cGy and 2400 cGy patient groups were off therapy for equivalent periods of time (range 70-123 mo) at follow-up testing. Mean age at diagnosis was 49 months, at testing: 142 months. The male to female ratio was 1/1. Standardized psychological tests were administered. Full-Scale, Verbal, and Performance IQ were measured with the Wechsler Intelligence Scale for Children-Revised. Wide Range Achievement Testing evaluated reading, spelling, and arithmetic abilities. Children treated with 1800 cGy performed significantly better than those who received 2400 cGy, and at the same level as controls. There were statistically significant differences between the 1800 cGy and 2400 cGy subjects in all measures. 2400 cGy patients had deficiencies in IQ and academic performance. 1800 cGy patients scored approximately 12 points higher than 2400 cGy children. Eleven children, two in the control group, two in the 1800 cGy, and seven in the 2400 cGy group had IQ scores of less than 90. Eight of the nine irradiated children with deficits had radiotherapy before age 5. These results indicate a mild, but diffuse information processing deficit in children who received 2400 cGy, but not in children who received 1800 cGy. These findings with a minimum of 6 years of follow-up provide new information on late effects of CNS prophylaxis in ALL. Reducing the cranial RT dose from 2400 cGy to 1800 cGy reduced neurotoxicity to acceptable levels.
Asunto(s)
Neoplasias Encefálicas/prevención & control , Encéfalo/efectos de la radiación , Cognición/efectos de la radiación , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevención & control , Dosificación Radioterapéutica , Niño , Trastornos del Conocimiento/etiología , Relación Dosis-Respuesta en la Radiación , Estudios de Seguimiento , Humanos , Leucemia-Linfoma Linfoblástico de Células Precursoras/radioterapiaRESUMEN
PURPOSE: To determine the clinical and functional outcomes of children undergoing limb-sparing therapy for extremity sarcomas. METHODS AND MATERIALS: We retrospectively reviewed 30 patients, age < or = 21 years, who were treated between l979 and l998 with external beam radiotherapy as a component of limb-sparing therapy for primary sarcomas of the extremity at UCSF. Included were patients for whom complete follow-up and functional outcome assessments were available. We assessed the patterns of failure, overall survival, disease-free survival, local control, and limb function. RESULTS: At a median follow-up of 3 years, 12 of the 30 patients recurred: 3 locally, 8 distantly, and 1 with synchronous local and distant disease as site of first progression. Eighteen patients were alive with no evidence of disease. The median overall survival was 10 years, with a median disease-free survival of 8 years. Functional outcome assessment revealed 15 patients retained excellent, 12 good, 1 fair, and 2 poor limb function. CONCLUSION: In pediatric patients receiving limb-sparing therapy, 90% maintained excellent or good limb function without compromising survival, demonstrating the validity of limb preservation in children with extremity sarcomas.
Asunto(s)
Extremidades , Sarcoma/radioterapia , Adolescente , Adulto , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Recurrencia Local de Neoplasia , Recuperación de la Función , Estudios Retrospectivos , Sarcoma/mortalidad , Análisis de Supervivencia , Insuficiencia del TratamientoRESUMEN
Fatal measles pneumonia developed in a 7-year-old boy who was in complete remission from acute lymphoblastic leukemia. There was no detectable antibody titer in two specimens taken eight days apart. Measles virus was grown from a lung biopsy taken shortely after hospital admission. Classical measles had been diagnosed in the patient and his siblings nine months previously. Immunosuppressed children who do not develop an antibody rise after a measles infection are at risk of later development of measles giant cell pneumonia. Suggestions are offered for the prevention of this often fatal complication.
Asunto(s)
Leucemia Linfoide/complicaciones , Sarampión/complicaciones , Neumonía Viral/complicaciones , Autopsia , Niño , Humanos , Pulmón/patología , Masculino , Sarampión/diagnóstico , Neumonía Viral/diagnósticoRESUMEN
Congenital immunodeficiency disorders such as severe combined immunodeficiency disease (SCID), Wiskott-Aldrich syndrome, and Chediak-Hegashi syndrome are almost uniformly fatal with most children dying before age one. Allogeneic bone marrow transplant (BMT) is the treatment of choice. Few of these children have matched donors. We use bone marrow processing techniques that allow us to utilize marrow from the parents. Children who lack HLA-identical donors are offered haploidentical, T-cell depleted parental BMTs. Some of these children do not have an immune deficiency severe enough to allow durable engraftment of processed mismatched bone marrow. Successful engraftment may necessitate the use of immunosuppression. Total body irradiation (TBI) is part of our intensive conditioning regimen for children with Wiskott-Aldrich and Chediak-Hegashi syndrome and most children with SCID who have undergone an unsuccessful prior mismatched, T-cell depleted BMT, or who have a high likelihood of donor marrow rejection based on pre-transplant immune function testing. TBI is considered extremely toxic therapy in infancy, with little information available on the acute and chronic effects. The 10 children presented in this report are among the youngest to have received TBI. Five patients were 2 to 6 months of age when they received TBI. The conditioning regimen for all patients was; antithymocyte globulin (25 mg/kg/day, x 3 days), cyclophosphamide (60 mg/kg/day, x 2 days), and TBI. 7.0 Gy TBI was given as a single dose AP-PA at approximately 15 cGy/min. Half value blocks shielded the brain, eyes and lungs. Six of 10 children were alive from 7 to 72 months post transplant.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Trasplante de Médula Ósea , Síndromes de Inmunodeficiencia/radioterapia , Irradiación Corporal Total/métodos , Preescolar , Terapia Combinada , Humanos , Síndromes de Inmunodeficiencia/congénito , Síndromes de Inmunodeficiencia/cirugía , LactanteRESUMEN
A male Chinese neonate had a melanocytic hamartoma that involved the entire orbit and the eye, but did not involve the orbital bones or eyelid skin. Although usually benign, these hamartomas may be locally invasive, and rare cases of malignant transformation have occurred.
Asunto(s)
Enfermedades de la Córnea/congénito , Neoplasias del Ojo/congénito , Hamartoma/congénito , Córnea/diagnóstico por imagen , Córnea/patología , Humanos , Recién Nacido , Masculino , Esclerótica/diagnóstico por imagen , Esclerótica/patología , Tomografía Computarizada por Rayos X , Úvea/diagnóstico por imagen , Úvea/patología , Neoplasias de la Úvea/diagnósticoRESUMEN
A 13-year-old girl developed an anaplastic astrocytoma of the cerebellum 7 years after irradiation of the central nervous system and prophylactic chemotherapy for acute lymphocytic leukemia. The fact that the astrocytoma was anaplastic and infiltrative was unusual for astroglial tumors at this site. It is proposed that this is a radiation-induced glioma.
Asunto(s)
Astrocitoma/patología , Neoplasias Cerebelosas/patología , Neoplasias Inducidas por Radiación/patología , Adolescente , Astrocitoma/diagnóstico por imagen , Astrocitoma/etiología , Neoplasias Cerebelosas/diagnóstico por imagen , Femenino , Humanos , Leucemia Linfoide/radioterapia , Neoplasias Inducidas por Radiación/diagnóstico por imagen , Neoplasias Inducidas por Radiación/etiología , Radioterapia/efectos adversos , Tomografía Computarizada por Rayos XRESUMEN
This is an interval analysis of the 2-year prospective multicenter Childrens Cancer Study Group study of 1,141 chronic venous access devices in 1,019 children with cancer. Device type was external catheter (EC) 72%, totally implantable (TID) 28%, and did not differ for diagnosis or age except more double-lumen devices in bone marrow transplant protocols (77%) and more TIDs in children less than 1 year old (17.7%). Insertion characteristics evaluated in 1,078 (95%) were: operating room placement 99%; general anesthesia 98%; cutdown 67%; percutaneous 33%; atrial position 50%, caval position 50%; and perioperative antibiotics 48%. Vein entry was the external jugular 33%, internal jugular 22%, subclavian 35%, cephalic 7%, and saphenous 3%. Insertion was difficult or very difficult in only 10% and operative complications occurred in only 0.7%. Degree of difficulty bore no relationship to device type or patient age. The reasons for removal in 736 devices (67%) were due to complications in 39%, of which infections were the most frequent. There was some variance between centers ranging from 8.5% to 31% for infection; 2.8% to 24% for dislodgment; and 0% to 13% for occlusion. ECs had a higher risk of dislodgment; elective removals were more frequent in TIDs; there was no difference in infection as a cause for removal between ECs and TIDs. Dislodgment was associated with the shortest distance of the cuff to the skin exit (mean, 4 cm): less than or equal to 2 cm, 49%; greater than 2 cm, 28% (P = .009) and occurred most frequently in the younger patient (18.9%, 0 to 1 years; 0.5%, greater than 8 years.
Asunto(s)
Cateterismo Venoso Central/instrumentación , Catéteres de Permanencia , Adolescente , Factores de Edad , Anestesia General , Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Infecciones Bacterianas/etiología , Cateterismo Venoso Central/efectos adversos , Cateterismo Venoso Central/métodos , Niño , Preescolar , Diseño de Equipo , Falla de Equipo , Humanos , Lactante , Venas Yugulares , Neoplasias/tratamiento farmacológico , Estudios Prospectivos , Sistema de Registros , Vena Subclavia , Incisión VenosaRESUMEN
The authors describe a 29-year-old man who had a 16-year history of neuroblastoma and uncommon manifestations. At age 13, he was diagnosed with stage III retroperitoneal ganglioneuroblastoma that was resected. Ten years later, bilateral testicular enlargement and a pelvic mass from infiltration of the neuroblastoma became palpable. Metastatic involvement was depicted with MIBG, a radiotracer that concentrates in tissues of the sympathetic nervous system. Using I-131 MIBG, the tumors were treated with therapeutic doses of radiation and a partial response was obtained. This case is unique because of the massive degree of bilateral testicular infiltration and its occurrence as a late manifestation of neuroblastoma in early adulthood.
Asunto(s)
Antineoplásicos/uso terapéutico , Ganglioneuroma/secundario , Radioisótopos de Yodo/uso terapéutico , Yodobencenos/uso terapéutico , Neoplasias Pélvicas/secundario , Neoplasias Retroperitoneales/cirugía , Neoplasias Testiculares/secundario , 3-Yodobencilguanidina , Adulto , Ganglioneuroma/diagnóstico por imagen , Ganglioneuroma/radioterapia , Humanos , Masculino , Neoplasias Pélvicas/diagnóstico por imagen , Neoplasias Pélvicas/radioterapia , Cintigrafía , Neoplasias Retroperitoneales/patología , Neoplasias Testiculares/diagnóstico por imagen , Neoplasias Testiculares/radioterapiaAsunto(s)
Trastornos de las Plaquetas Sanguíneas/genética , Sordera/genética , Nefritis/genética , Adenosina Difosfato/análisis , Adenosina Trifosfato/análisis , Adolescente , Adulto , Coagulación Sanguínea , Trastornos de las Plaquetas Sanguíneas/complicaciones , Trastornos de las Plaquetas Sanguíneas/patología , Trastornos de las Plaquetas Sanguíneas/fisiopatología , Plaquetas/análisis , Médula Ósea/patología , Preescolar , Colágeno , Sordera/complicaciones , Femenino , Humanos , Riñón/patología , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Nefritis/complicaciones , Nefritis/patología , Linaje , Adhesividad Plaquetaria , Trombocitopenia/genéticaAsunto(s)
Leucemia/diagnóstico , Preescolar , Humanos , Leucemia/mortalidad , Leucemia/terapia , PronósticoAsunto(s)
Leucemia/diagnóstico , Niño , Humanos , Leucemia/tratamiento farmacológico , Leucemia/mortalidad , PronósticoAsunto(s)
Neoplasias de las Glándulas Suprarrenales/complicaciones , Ataxia/complicaciones , Movimientos Oculares , Ganglios Autónomos , Ganglioneuroma/complicaciones , Neoplasias del Mediastino/complicaciones , Mioclonía/complicaciones , Neuroblastoma/complicaciones , Neoplasias de las Glándulas Suprarrenales/diagnóstico por imagen , Neoplasias de las Glándulas Suprarrenales/tratamiento farmacológico , Neoplasias de las Glándulas Suprarrenales/radioterapia , Neoplasias de las Glándulas Suprarrenales/cirugía , Neoplasias de las Glándulas Suprarrenales/orina , Preescolar , Ciclofosfamida/uso terapéutico , Femenino , Ganglioneuroma/diagnóstico por imagen , Ganglioneuroma/tratamiento farmacológico , Ganglioneuroma/radioterapia , Ganglioneuroma/cirugía , Ganglioneuroma/orina , Humanos , Lactante , Masculino , Neoplasias del Mediastino/diagnóstico por imagen , Neoplasias del Mediastino/terapia , Neoplasias del Mediastino/orina , Neuroblastoma/diagnóstico , Neuroblastoma/diagnóstico por imagen , Neuroblastoma/tratamiento farmacológico , Neuroblastoma/radioterapia , Neuroblastoma/cirugía , Neuroblastoma/orina , Urografía , Ácido Vanilmandélico/orinaAsunto(s)
Neoplasias de Células Germinales y Embrionarias/patología , Adulto , Antineoplásicos/administración & dosificación , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/terapia , Niño , Gonadotropina Coriónica/análisis , Quimioterapia Combinada , Femenino , Humanos , Masculino , Neoplasias de Células Germinales y Embrionarias/metabolismo , Neoplasias de Células Germinales y Embrionarias/terapia , Neoplasias Ováricas/patología , Neoplasias Ováricas/terapia , Pronóstico , Neoplasias Testiculares/patología , Neoplasias Testiculares/terapia , alfa-Fetoproteínas/análisisRESUMEN
The current literature in supportive care of the immunocompromised patient has shown a trend toward change in, perhaps reflecting, at least in the American literature, the national emphasis on health delivery, access, and quality of life issues. This review reflects that shift. Considerable attention is given to psychosocial issues, accessibility to care at special pediatric cancer centers, and the special problems of the adolescent. In keeping with this shift in national interest, several reports deal with the prophylaxis of infection as opposed to the treatment of established disease and the strategy of avoiding chemotherapy-related late effects in children with curable disease.
Asunto(s)
Infecciones Bacterianas/prevención & control , Tolerancia Inmunológica , Adolescente , Niño , Humanos , Neoplasias/terapia , Psicología del Adolescente , Virosis/prevención & controlRESUMEN
The presence of very high numbers of circulating leukemic blast cells is reported to be associated with an increased risk of fatal complications secondary to hyperviscosity of blood and leukostasis, tumor lysis causing metabolic derangements, intravascular coagulopathy, and proliferation of leukemic cells in the brain leading to intracranial hemorrhage. Transfusions of red cells further increases the possibility of fatal leukostasis. Recommendations for care of these patients include adequate hydration, alkalinization, control of uric acid production with allopurinol, correction of the many possible fluid and electrolyte problems, possible use of hemodialysis, avoidance of excessive transfusions, and the careful use of antileukemic drugs at the outset of therapy. Cranial radiation, leukapheresis, and exchange transfusions have been used in the hope of preventing the sometimes fatal complications in leukemic patients with hyperleukocytosis. However, the effectiveness of these techniques remains in question.
Asunto(s)
Leucemia/complicaciones , Leucocitosis/etiología , Enfermedad Aguda , Adolescente , Viscosidad Sanguínea , Niño , Preescolar , Humanos , Leucemia/sangre , Leucocitosis/sangre , Leucocitosis/terapia , Ácido Úrico/orinaRESUMEN
The role of exenterative surgical therapy in pelvic rhabdomyosarcoma has been progressively diminishing with the increasing effectiveness of combination chemotherapy. Cooperative studies have demonstrated that, in most instances, the initial surgical procedure should consist of a thorough examination under anesthesia and a biopsy of the mass. Surgery should be repeated to evaluate the therapeutic response to chemotherapy (with or without radiation treatment) so that radical resection, when necessary, is not unduly delayed. In some instances, patients who responded only partially to treatment will, with limited surgical excision, demonstrate a complete response on pathologic examination. The late effects of this multidisciplinary treatment plan must be studied further and long-term follow-up for these children is imperative.